关于《振德医疗用品股份有限公司股票交易异常波动 问询函》的回函 振德医疗用品股份有限公司: 本人于 2025 年 9 月 15 日收到贵公司发来的《振德医疗用品股份 有限公司股票交易异常波动问询函》,经自查核实,回复如下: 本人控制的浙江振德控股有限公司(以下简称"浙江振德")及 其全资子公司许昌振德园林绿化工程有限公司(以下简称"许昌园林") 于 2025 年 9 月 10 日与孙纪木、中国工商银行股份有限公司绍兴分 行签署了《关于振德医疗用品股份有限公司股份转让协议》,浙江振 德、许昌园林拟将其持有的合计 13,322,560 股贵公司无限售条件流通 股(占贵公司总股本 5.00%)通过协议转让的方式以人民币 26.74 元/ 股的价格转让给孙纪木(其中浙江振德拟转让 1,548,620 股,占贵公 司总股本的 0.58%;许昌园林拟转让 11,773,940 股,占贵公司总股本 的 4.42%),转让价款共计人民币 356,245,254.40 元。振德医疗已于 2025年9月 11日在上海证券交易所网站披露该事项详细内容。 本次协议转让事项尚需履行上海证券交易所合规性审核,并在中 国证券登记结算有限责 ...

Group 1 - The stock of Zhendemedical increased by 6.90% today, with a trading volume of 1.109 billion yuan and a turnover rate of 11.48% [1] - The post-market data shows that the Shanghai Stock Connect special seat bought 52.31 million yuan and sold 54.90 million yuan [1] - One institutional special seat had a net sell of 102 million yuan [1]

Group 1 - The core viewpoint of the news is the performance and financial metrics of Zhendemedical, which saw a stock price increase of 5.08% to 37.45 CNY per share, with a trading volume of 1.007 billion CNY and a turnover rate of 10.47%, leading to a total market capitalization of 9.979 billion CNY [1] - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, specializes in the production, research, and sales of medical dressings, with its main business revenue composition being: surgical infection control 43.04%, basic care 20.46%, ostomy and modern wound care 18.59%, pressure treatment and fixation 10.75%, infection control protection 6.58%, and others 0.58% [1] Group 2 - From the perspective of major fund holdings, Xiangcai Fund has a significant position in Zhendemedical, with its Xiangcai Medical Health Mixed A Fund (019958) increasing its holdings by 10,000 shares to a total of 40,000 shares, representing 4.59% of the fund's net value, ranking as the eighth largest holding [2] - The Xiangcai Medical Health Mixed A Fund (019958) was established on December 26, 2023, with a latest scale of 13.2808 million CNY, achieving a year-to-date return of 50.36%, ranking 846 out of 8246 in its category, and a one-year return of 67.97%, ranking 1687 out of 8054 [2] Group 3 - The fund manager of Xiangcai Medical Health Mixed A Fund is Zhang Quan, who has been in the position for 1 year and 265 days, managing total assets of 18.3775 million CNY, with the best fund return during his tenure being 74.42% and the worst being 73.66% [3]

Core Insights - Zhendemedical's trading volume reached 1.004 billion RMB, marking the highest level since December 23, 2020 [2] - The latest stock price increased by 4.88%, with a turnover rate of 10.45% [2] - The previous trading day's total transaction volume for the stock was 237 million RMB [2] Company Overview - Zhendemedical was established on August 18, 1994, with a registered capital of 2.66451202 billion RMB [2]

Core Viewpoint - The stock price of Zhendemedical (603301.SH) has surged, achieving three limit-up days in four trading sessions, primarily due to the strategic investment by steel magnate Sun Jimu [2][3]. Group 1: Stock Performance - Zhendemedical's stock price opened high and reached the limit-up within four minutes on September 12, marking its third limit-up in four trading days [2]. - The stock price was transferred at 26.74 CNY per share, approximately 10% lower than the previous closing price of 29.71 CNY [3]. Group 2: Share Transfer Details - The controlling shareholder, Zhejiang Zhendemedical Holdings Co., Ltd., and its subsidiary plan to transfer a total of 5% of the company's shares to Sun Jimu for a total consideration of 356 million CNY [3]. - The share transfer includes 1,332,600 shares, with Zhejiang Zhendemedical transferring 154,860 shares and its subsidiary transferring 1,177,390 shares [3][4]. Group 3: Company Background - Zhendemedical specializes in the production, research, and sales of medical dressings, with products distributed in over 70 countries and regions, generating approximately 60% of its revenue from overseas markets [3][8]. - The company has established a strong market presence, covering over 9,200 hospitals in China, including more than 1,200 top-tier hospitals [8][9]. Group 4: Financial Performance - Zhendemedical's net profit has shown volatility, with figures of 596 million CNY, 681 million CNY, 198 million CNY, and 385 million CNY from 2021 to 2024, and a net profit of 128 million CNY in the first half of 2025 [9][10]. - The company has consistently paid dividends since its listing in 2018, distributing a total of 1.46 billion CNY in cash dividends with an average payout ratio of 30.26% [11].

Group 1 - Junshi Bioscience's product Mindewei achieved full-channel coverage in the first half of 2025, exploring community and county market medical cooperation models [1] - Mindewei was conditionally approved for marketing by the National Medical Products Administration in January 2023, and the company has actively built a commercialization team [1] - The company has established strategic partnerships with national pharmaceutical companies and chain pharmacies, and is exploring sales models on platforms like Meituan, JD, and Alibaba Health [1] Group 2 - Changchun High-tech's subsidiary GS3-007a dry mixed suspension has received acceptance for its clinical trial application, aimed at treating pediatric growth hormone deficiency (PGHD) [2] - PGHD is a common endocrine disease in pediatrics, with an incidence rate of approximately 1 in 8600 in China, primarily caused by insufficient secretion of growth hormone-releasing hormone [2] Group 3 - Chengda Biologics has gained market access for its human rabies vaccine in Indonesia and is actively expanding into larger markets like Brazil [3] - The company's international business has shown significant growth, covering over 30 countries, and is advancing its "vaccine going abroad" strategy [3] Group 4 - Taiji Group's subsidiary has received clinical trial approval for semaglutide injection, targeting blood sugar control in adults with type 2 diabetes [4] - The indication includes patients whose blood sugar remains uncontrolled despite diet and exercise, and those at risk of major cardiovascular events [4] Group 5 - China National Pharmaceutical Group plans to strengthen accounts receivable management and establish a tracking ledger for key customers [5] - The company reported a net cash flow of -546 million yuan in the first half of 2025, a significant improvement from -743 million yuan in the same period last year [5] Group 6 - Zhend Medical expects its African production base to break even by the end of the year while actively advancing the construction of its Mexican production base [6][7] - The company is focusing on expanding into emerging markets with increasing demand for basic medical supplies and is enhancing operational efficiency in its African base [6][7]

Core Viewpoint - On September 11, 2025, Zhend Medical (603301) closed at 32.4 yuan, reaching the daily limit with a 10.02% increase, indicating strong market interest and trading activity [1][4]. Trading Information Summary - Zhend Medical's stock hit the daily limit at 9:42 AM, with a closing price of 32.4 yuan and a turnover rate of 6.04%, totaling a trading volume of 160,900 lots and a transaction value of 515 million yuan [1]. - The net inflow of main funds was 88.9 million yuan, accounting for 17.27% of the total transaction value, while retail investors experienced a net outflow of 34.96 million yuan, representing 6.79% of the total [1]. Company Announcement Summary - Zhend Medical announced that Sun Jimu acquired 13,322,560 shares, representing 5.00% of the total share capital, through a share transfer agreement at a price of 26.74 yuan per share, totaling approximately 356.25 million yuan [2][3]. - Following this transfer, the holding percentage of the controlling shareholder, Zhejiang Zhend, and its subsidiaries decreased from 59.20% to 54.20%, while Sun Jimu's holding increased to 5.00% [2][3]. - The transfer is subject to compliance review by the Shanghai Stock Exchange and requires the release of existing share pledges before the transfer can be completed [2][3].

Core Viewpoint - The company is focusing on expanding its overseas production bases and enhancing strategic partnerships with international clients to meet the diversified supply chain demands in the current market environment [1] Group 1: Overseas Market Strategy - The company plans to continue the construction, production, and operation of overseas production bases to leverage its global supply chain advantages [1] - There is an emphasis on strengthening strategic cooperation with international clients, particularly core major clients, to capture more business opportunities and market share [1] Group 2: Emerging Market Focus - The company aims to address the rapidly increasing demand for basic medical consumables in emerging markets, particularly in Southeast Asia, North America, and South America [1] - The company will enhance its investment in these regions, utilizing its product portfolio, quality control, and cost management advantages to increase global market coverage and penetration [1] Group 3: Operational Efficiency - The company's African production base, which commenced operations in the second half of last year, is expected to achieve profitability by the end of this year [1] - The company is also actively advancing the construction of its production base in Mexico [1]

Core Viewpoint - Zhendemedical announced the transfer of 5% of its shares from its controlling shareholder to Sun Jimu for approximately 356 million yuan, with a share price set at 26.74 yuan [1][2] Group 1: Share Transfer Details - Zhejiang Zhendemedical and its action-in-concert party, Xuchang Garden, will transfer a total of 13.32 million shares, representing 5% of the company's total share capital [1] - After the transfer, Zhejiang Zhendemedical's shareholding will decrease to 144 million shares, maintaining a controlling stake of 54.20%, while Xuchang Garden will exit completely [1] - Sun Jimu will acquire 13.32 million shares, holding 5.00% of the company post-transfer [1] Group 2: Stock Market Reaction - Following the announcement, Zhendemedical's stock price surged to a limit-up, closing at 32.4 yuan, resulting in a market capitalization of 8.633 billion yuan [2] Group 3: Company Performance - Zhendemedical's main business includes the R&D, production, and sales of medical and health products, with a product line covering health protection, wound care, and home cleanliness [2] - The company reported fluctuating profitability, with revenues of 6.138 billion yuan in 2022, 4.127 billion yuan in 2023, and projected 4.264 billion yuan in 2024, alongside net profits of 680 million yuan, 198 million yuan, and 385 million yuan respectively [2] - In the first half of this year, Zhendemedical achieved revenue of 2.1 billion yuan, a year-on-year increase of 2.83%, while net profit decreased by 20.61% to 128 million yuan [2] Group 4: Profile of the Acquirer - Sun Jimu, referred to as a "steel tycoon," is the chairman of Hebei Xinhua United Metallurgical Holding Group, ranked 42nd in the 2025 China Private Enterprises 500 [3] - He appeared on the 2024 Hurun Global Rich List with a net worth of 24 billion yuan [3] - Sun Jimu has a history of investments in various companies, including Jin Gu shares and has been a significant shareholder in several listed companies [3]

Core Viewpoint - Zhend Medical (振德医疗) experienced a 10.02% increase in stock price, closing at 32.40 yuan, following the announcement of a share transfer agreement involving its controlling shareholder and related parties [1] Group 1: Share Transfer Agreement - The controlling shareholder, Zhejiang Zhend Holdings Co., Ltd. (浙江振德), and its wholly-owned subsidiary, Xuchang Zhend Landscaping Engineering Co., Ltd. (许昌园林), signed a share transfer agreement to transfer a total of 13,322,560 shares, representing 5.00% of the company's total share capital, at a price of 26.74 yuan per share [1][2] - The total consideration for the share transfer amounts to 356,245,254.40 yuan [1] Group 2: Shareholding Structure Changes - Prior to the transfer, Zhejiang Zhend and its concerted actors held a total of 157,748,066 shares, accounting for 59.20% of the total share capital. Post-transfer, their holdings will decrease to 144,425,506 shares, representing 54.20% [2] - The new shareholder, Sun Jimu (孙纪木), will hold 13,322,560 shares, which is 5.00% of the total share capital [2] Group 3: Regulatory Compliance - The share transfer does not trigger a mandatory tender offer, does not constitute a related party transaction, and will not result in changes to the controlling shareholder or actual controller of the company [3]